Myeloperoxidase (MPO): inflammation marker that can serve as cardiac marker.

16 Feb, 2017


no comments

Here at Advanced ImmunoChemical, Inc., we announce a new generation of anti-MPO monoclonal antibodies suitable for the development of quantitative MPO immunoassay. Sandwich immunoassays utilizing these antibodies demonstrated exceptionable results in precise MPO immunodetection in patient’s blood samples as shown in our AssayNotes:

Click here for Myeloperoxidase AssayNotes and product information.

MPO causes oxidative modification of low density lipoprotein (LDL) to a high uptake form that is considered to be a key event in the promotion of atherogenesis and in the initiation and progression of cardiovascular diseases (1). MPO possesses potent proinflammatory properties and is shown to be involved in pathogenesis of lung cancer (2), Alzheimer’s disease (3) and multiple sclerosis (4).

Myeloperoxidase (MPO) is a hemoprotein that is abundantly expressed in polymorphonuclear leukocytes (neutrophils) and secreted during their activation. Native MPO is a covalently bound tetrameric complex of two glycosylated alpha chains (MW 59 – 64 kDa) and two unglycosylated beta chains (MW 14 kDa) with total MW about 150 kDa and theoretical pI 9.2 (5).

Recently it was demonstrated that an increased MPO level in patient’s blood serves as a risk marker for atherosclerosis (6) and coronary artery disease (7). MPO was also shown to give an early risk warning of myocardial infarction, as well as the risk of other major adverse cardiac events in patients with chest pain in the ensuing 30-day and 6-month periods (8, 9).

The value of MPO as a marker is in that MPO predicts these outcomes independently of other known laboratory tested risk factors, including troponins, creatine kinase MB isoform (CK-MB), C-reactive protein (CRP) and lipid profile. Moreover, unlike troponins I and T, CK-MB, and CRP, MPO makes it possible to identify patients at risk for cardiac events in the absence of myocardial necrosis (8). All these factors make MPO measurements in patients an indispensable procedure to reveal patients with chest pain that are at increased risk of cardiovascular complications.

Myeloperoxidase and Myeloperoxidase-related Products available at our website:

Monoclonal Mouse Anti-human Myeloperoxidase (MPO)

Myeloperoxidase Antigen (MPO)

Myeloperoxidase-free Serum


  1. Klebanoff, S.J. (2005). Myeloperoxidase: friend and foe. J Leukos Biol 77, 598-625.
  2. Chevrier, I, et al. (2003). Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics, 13(12), 729-739.
  3. Reynolds, W.F. et al. (2000) MPO and APOEpsilon4 polymorphisms interact to increase risk for in Finnish males. Neurology 55(9), 1284-1290.
  4. Nagra, R.M., et al. (1997). Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple schlerosis. J. Neuroimunol 78(1-2), 97-107.
  5. Nauseef, W.M. et al. (1988). Biosynthesis and processing of myeloperoxidase- a markewr for myeloid cell differentyiation. Eur J Haematol 40(2), 97-110.
  6. Nambi, V. (2005). The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 7(2), 127-131.
  7. Zhang, R., et al. (2001). Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286(17), 2136-2142.
  8. Brennan, ML, et al. (2003). Prognostic value of myeloperoxidase in patients with chest pain. New Eng J Med. 349(17), 1595-1604.
Skip to toolbar